logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Treatmentresistant Depressive Disorder

    Medications for Treatmentresistant Depressive Disorder

    FiltersReset Filters
    3 results

    • fluoxetine

      (Fluoxetine)
      Cadila Pharmaceuticals Limited
      Usage: Fluoxetine capsules are indicated for treating Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder. They can be combined with Olanzapine for Bipolar I Disorder and Treatment Resistant Depression. Monotherapy is not approved for Bipolar I or treatment-resistant cases.

    • olanzapine

      (Olanzapine)
      Macleods Pharmaceuticals Limited
      Usage: Olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia, bipolar I disorder (both manic/mixed episodes and as adjunctive therapy), depressive episodes associated with bipolar I disorder (in combination with fluoxetine), and treatment-resistant depression (also with fluoxetine). Caution is advised in pediatric patients due to potential risks.

    • olanzapine

      (Olanzapine)
      Cadila Pharmaceuticals Limited
      Usage: Olanzapine is indicated for treating schizophrenia, bipolar I disorder (manic or mixed episodes), acute agitation in schizophrenia and bipolar I mania, and in combination with fluoxetine for depressive episodes in bipolar I disorder and treatment-resistant depression. Use in adolescents requires careful risk assessment due to potential side effects.